Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors-Reference-Cited by-同舟云学术

Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors

Published:2015-07-09 Issue:28 Volume:6 Page:24904-24911
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Chen Qi¹²³,Quan Qi¹²³,Ding Lingyu¹²³,Hong Xiangchan¹²³,Zhou Ningning¹²³,Liang Ying¹²³,Wu Haiying¹²³

Affiliation:

1. State Key Laboratory of Oncology in South China, Guangzhou, China

2. Department of Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China

3. Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds;BMC Pulmonary Medicine;2021-07-01

Radiofrequency Ablation with Continued EGFR Tyrosine Kinase Inhibitor Therapy Prolongs Disease Control in EGFR-Mutant Advanced Lung Cancers with Acquired Resistance to EGFR Tyrosine Kinase Inhibitors: Two Case Reports

;OncoTargets and Therapy;2020-07

3. miR‐143 inhibits renal cell carcinoma cells metastatic potential by suppressing ABL2;The Kaohsiung Journal of Medical Sciences;2020-03-20

4. Local Thermal Ablation with Continuous EGFR Tyrosine Kinase Inhibitors for EGFR-Mutant Non-small Cell Lung Cancers that Developed Extra-Central Nervous System (CNS) Oligoprogressive Disease;CardioVascular and Interventional Radiology;2019-01-30

5. Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial;Lung Cancer;2018-10